phospho-Beta catenin (Tyr86)抗体特异性结合抗原：抗体本身不能直接溶解或杀伤带有特异抗原的靶细胞，通常需要补体或吞噬细胞等共同发挥效应以**病原微生物或导致病理损伤。然而，抗体可通过与病毒或**的特异性结合，直接发挥中和病毒的作用。
产品编号xy- 4074R
英文名称phospho-Beta catenin (Tyr86)
中文名称磷酸化β 连环素蛋白抗体
别 名beta Catenin (phospho Y86); Beta catenin(phospho Tyr86); p-beta Catenin (Y86); p-Beta catenin(Tyr86); beta-catenin; beta catenin; CTNNB1; CHBCAT; CTNNB1; CTNNB; PRO2286; Cadherin associated protein; Catenin (cadherin associated protein), beta 1, 88kDa; Catenin beta 1; Catenin beta-1; CATNB; CTNB1_HUMAN; CTNNB; CTNNB1; DKFZp686D02253; FLJ25606; FLJ37923; b-catenin; OTTHUMP00000162082; OTTHUMP00000165222; OTTHUMP00000165223; OTTHUMP00000209288; OTTHUMP00000209289; Catenin-β; Catenin β.
说 明 书100ul
产品类型磷酸化抗体
研究领域肿瘤 **学 细胞凋亡 细胞粘附分子
抗体来源Rabbit
克隆类型Polyclonal
phospho-Beta catenin (Tyr86)抗体交叉反应 Human, Mouse, Rat, Chicken, Pig, Cow, Horse, Rabbit,
产品应用WB=1:500-2000 ELISA=1:500-1000 IHC-P=1:400-800 IHC-F=1:400-800 Flow-Cyt=1μg/Test ICC=1:100-500 IF=1:100-500 （石蜡切片需做抗原修复）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量86kDa
细胞定位细胞核 细胞浆 细胞膜 细胞外基质
性 状Lyophilized or Liquid
浓 度1mg/ml
免 疫 原KLH conjugated Synthesised phosphopeptide derived from human Beta-catenin around the phosphorylation site of Tyr86:GQ(p-Y)AM
亚 型IgG
纯化方法affinity purified by Protein A
储 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
phospho-Beta catenin (Tyr86)抗体保存条件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
PubMedPubMed
产品介绍background:
The protein encoded by this gene is part of a complex of proteins that constitute adherens junctions (AJs). AJs are necessary for the creation and maintenance of epithelial cell layers by regulating cell growth and adhesion between cells. The encoded protein also anchors the actin cytoskeleton and may be responsible for transmitting the contact inhibition signal that causes cells to stop dividing once the epithelial sheet is complete. Finally, this protein binds to the product of the APC gene, which is mutated in adenomatous polyposis of the colon. Mutations in this gene are a cause of colorectal cancer (CRC), pilomatrixoma (PTR), medulloblastoma (MDB), and ovarian cancer. Three transcript variants encoding the same protein have been found for this gene.[provided by RefSeq, Oct 2009].
Function:
Key downstream component of the canonical Wnt signaling pathway. In the absence of Wnt, forms a complex with AXIN1, AXIN2, APC, CSNK1A1 and GSK3B that promotes phosphorylation on N-terminal Ser and Thr residues and ubiquitination of CTNNB1 via BTRC and its subsequent degradation by the proteasome. In the presence of Wnt ligand, CTNNB1 is not ubiquitinated and accumulates in the nucleus, where it acts as a coactivator for transcription factors of the TCF/LEF family, leading to activate Wnt responsive genes. Involved in the regulation of cell adhesion. Acts as a negative regulator of centrosome cohesion. Involved in the CDK2/PTPN6/CTNNB1/CEACAM1 pathway of insulin internalization. Blocks anoikis of malignant kidney and intestinal epithelial cells and promotes their anchorage-independent growth by down-regulating DAPK2. Disrupts PML function and PML-NB formation by inhibiting RANBP2-mediated sumoylation of PML.
Subunit:
Two separate complex-associated pools are found in the cytoplasm. The majority is present as component of an E-cadherin/ catenin adhesion complex composed of at least E-cadherin/CDH1 and beta-catenin/CTNNB1, and possibly alpha-catenin/CTNNA1; the complex is located to adherens junctions. The stable association of CTNNA1 is controversial as CTNNA1 was shown not to bind to F-actin when assembled in the complex. Alternatively, the CTNNA1-containing complex may be linked to F-actin by other proteins such as LIMA1. Another cytoplasmic pool is part of a large complex containing AXIN1, AXIN2, APC, CSNK1A1 and GSK3B that promotes phosphorylation on N-terminal Ser and Thr residues and ubiquitination of CTNNB1 via BTRC and its subsequent degradation by the proteasome. Wnt-dependent activation of DVL antagonizes the action of GSK3B. When GSK3B activity is inhibited the complex dissociates, CTNNB1 is dephosphorylated and is no longer targeted for destruction. The stabilized protein translocates to the nucleus, where it binds TCF/LEF-1 family members, TBP, BCL9 and possibly also RUVBL1 and CHD8. Binds CTNNBIP and EP300. CTNNB1 forms a ternary complex with LEF1 and EP300 that is disrupted by CTNNBIP1 binding (By similarity). Interacts with TAX1BP3 (via the PDZ domain); this interaction inhibits the transcriptional activity of CTNNB1 (By similarity). Interacts with AJAP1, BAIAP1, CARM1, CTNNA3, CXADR and PCDH11Y. Binds SLC9A3R1. Interacts with GLIS2 and MUC1. Interacts with SLC30A9. Interacts with XIRP1 (By similarity). Interacts directly with AXIN1; the interaction is regulated by CDK2 phosphorylation of AXIN1 (By similarity). Interacts with SCRIB (By similarity). Interacts with PTPRU (via the cytoplasmic juxtamembrane domain). Interacts with EMD. Interacts with TNIK and TCF7L2. Interacts with SESTD1 and TRPC4. Interacts with CAV1. Interacts with TRPV4. The TRPV4 and CTNNB1 complex can interact with CDH1. Interacts with VCL (By similarity). Interacts with PTPRJ. Interacts with PKT7 and CDK2. Interacts with FAT1 (via the cytoplasmic domain) (By similarity). Interacts with NANOS1 and NDRG2. Interacts with isoform 1 of NEK2. Interacts with both isoform 1 and isoform 2 of CDK5. Interacts with PTK6. Interacts with SOX7; this interaction may lead to proteasomal degradation of active CTNNB1 and thus inhibition of Wnt/beta-catenin-stimulated transcription. Identified in a complex with HINT1 and MITF. Interacts with FHIT. The CTNNB1 and TCF4 complex interacts with PML (isoform PML-4). Interacts with FERMT2. Identified in a complex with TCF4 and FERMT2.
Subcellular Location:
Cytoplasm. Nucleus. Cytoplasm, cytoskeleton. Cell junction, adherens junction. Cell junction. Cell membrane. Cytoplasm, cytoskeleton, centrosome. Cytoplasm, cytoskeleton, spindle pole. Note=Cytoplasmic when it is unstabilized (high level of phosphorylation) or bound to CDH1. Translocates to the nucleus when it is stabilized (low level of phosphorylation). Interaction with GLIS2 and MUC1 promotes nuclear translocation. Interaction with EMD inhibits nuclear localization. The majority of beta-catenin is localized to the cell membrane. In interphase, colocalizes with CROCC between CEP250 puncta at the proximal end of centrioles, and this localization is dependent on CROCC and CEP250. In mitosis, when NEK2 activity increases, it localizes to centrosomes at spindle poles independent of CROCC. Co-localizes with CDK5 in the cell-cell contacts and plasma membrane of undifferentiated and differentiated neuroblastoma cells.
Tissue Specificity:
Expressed in several hair follicle cell types: basal and peripheral matrix cells, and cells of the outer and inner root sheaths. Expressed in colon. Present in cortical neurons (at protein level).
Post-translational modifications:
Phosphorylation at Ser-552 by AMPK promotes stabilizion of the protein, enhancing TCF/LEF-mediated transcription. Phosphorylation by GSK3B requires prior phosphorylation of Ser-45 by another kinase. Phosphorylation proceeds then from Thr-41 to Ser-37 and Ser-33. Phosphorylated by NEK2. EGF stimulates tyrosine phosphorylation. Phosphorylation on Tyr-654 decreases CDH1 binding and enhances TBP binding. Phosphorylated on Ser-33 and Ser-37 by HIPK2. This phosphorylation triggers proteasomal degradation. Phosphorylation on Ser-191 and Ser-246 by CDK5. Phosphorylation by CDK2 regulates insulin internalization. Phosphorylation by PTK6 at Tyr-64, Tyr-142, Tyr-331 and/or Tyr-333 with the predominant site at Tyr-64 is not essential for inhibition of transcriptional activity.
Ubiquitinated by the SCF(BTRC) E3 ligase complex when phosphorylated by GSK3B, leading to its degradation. Ubiquitinated by a E3 ubiquitin ligase complex containing UBE2D1, SIAH1, CACYBP/SIP, SKP1, APC and TBL1X, leading to its subsequent proteasomal degradation (By similarity).
S-nitrosylation at Cys-619 within adherens junctions promotes VEGF-induced, NO-dependent endothelial cell permeability by disrupting interaction with E-cadherin, thus mediating disassembly adherens junctions.
DISEASE:
Colorectal cancer (CRC) [MIM:114500]: A complex disease characterized by malignant lesions arising from the inner wall of the large intestine (the colon) and the rectum. Genetic alterations are often associated with progression from premalignant lesion (adenoma) to invasive adenocarcinoma. Risk factors for cancer of the colon and rectum include colon polyps, long-standing ulcerative colitis, and genetic family history. Note=The gene represented in this entry may be involved in disease pathogenesis.
Note=Activating mutations in CTNNB1 have oncogenic activity resulting in tumor development. Somatic mutations are found in various tumor types, including colon cancers, ovarian and prostate carcinomas, hepatoblastoma (HB), hepatocellular carcinoma (HCC). HBs are malignant embryonal tumors mainly affecting young children in the first three years of life.
Pilomatrixoma (PTR) [MIM:132600]: Common benign skin tumor. Note=The disease is caused by mutations affecting the gene represented in this entry.
Medulloblastoma (MDB) [MIM:155255]: Malignant, invasive embryonal tumor of the cerebellum with a preferential manifestation in children. Note=The gene represented in this entry may be involved in disease pathogenesis.
Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.
Note=A chromosomal aberration involving CTNNB1 is found in salivary gland pleiomorphic adenomas, the most common benign epithelial tumors of the salivary gland. Translocation t(3;8)(p21;q12) with PLAG1.
Mesothelioma, malignant (MESOM) [MIM:156240]: An aggressive neoplasm of the serosal lining of the chest. It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos. Note=The gene represented in this entry may be involved in disease pathogenesis.
Similarity:
Belongs to the beta-catenin family.
Contains 12 ARM repeats.
SWISS:
P35222
Gene ID:
1499
phospho-Beta catenin (Tyr86)抗体（antibody,
Ab）是由效应B细胞（效应**B细胞）分泌，机体用于抵御外来物质，如病毒，**等抗原，结构呈“Y”字型的球状蛋白质，仅仅存在于脊椎动物的血液和B**细胞膜表面。凡是能够跟抗体结合的物质，均被称作抗原，因此对于抗抗体（能够结合抗体的抗体）来说，抗体本身也是一种抗原物质。
phospho-Beta catenin (Tyr86)抗体普通抗体重链和轻链的结构
重链结构：普通的**球蛋白具有2条重链（H链），分子量约为50kD,有μ、δ、γ、ε和α五种重链亚型，对应的**球蛋白名称分别为IgM、IgG、IgA、IgD和IgE。
轻链结构： 普通**球蛋白具有2条轻链（L链），分子质量约25kDa，有κ链和λ链两种亚型，这两种轻链决定了Ig的亚型类别（IgG1，IgG2，IgG3，IgG4）。一个天然的Ig分子两条轻链总是相同的，但在同一个体内可存在分别带有κ或λ链的抗体分子。不同种属生物体内两型轻链的比例不同，正常人血清**球蛋白κ链：λ链约为2：1，而在小鼠的比例为20：1。
2.2抗体Fab段和Fc段
IgG经木瓜蛋白酶酶切后裂解为2个完全相同的Fab段和1个Fc段,每个Fab段都为单价,可与抗原结合但不会再发生凝集反应；经胃蛋白酶酶切后裂解为1个完整F(ab)2片段和碎片化的Fc片段,F(ab’)2片段为双价,可同时结合两个抗原表位。Fab段为抗原结合片段（fragment of antigen binding，Fab），相当于抗体分子的两个臂，由一个完整的轻链和重链的VH和CH1结构域组成。Fc段为可结晶段（fragment crystallizable，Fc）相当于Ig的CH2和CH3结构域，是Ig与效应分子或者细胞相互作用的部位。Fab段包含完整的可变区，以及恒定区的CH1区域。Fc段仅指Ig恒定区CH2和CH3的区域，相当于Y字结构下面那一部分。
合格 合格 Phospho-PAK4(Ser474) + PAK5(Ser602) + PAK6(Ser560) 磷酸化p21激活激酶4/5/6抗体
合格 Phospho-PDGFRA(Tyr849)/PDGFRB(Tyr857) 磷酸化血小板源性生长因子受体α/β抗体
合格 Phospho-PBK (Thr9) 磷酸化PDZ连接激酶/T-LAK细胞源蛋白激酶抗体
合格 合格 Phospho-PDK1(Ser241) 磷酸化3磷酸肌醇依赖性蛋白激酶1
合格 Phospho-PERK(Thr980) 磷酸化蛋白激酶样内质网激酶抗体
合格 合格 phospho-PI3 kinase p85 alpha + gamma (Tyr467 + Tyr199) 磷酸化磷脂酰肌醇激酶/PI3 Kinase P85α/γ抗体
合格 合格 Phospho-PKR (Thr451) 磷酸化蛋白激酶R抗体
合格 Phospho-PKR (Thr446 + Thr451) 磷酸化蛋白激酶R抗体
合格 合格 Phospho-PLCG 2 (Tyr1217) 磷酸化磷酯酶Cγ2抗体
合格 合格 Phospho-PLC beta3 (Ser1105) 磷酸化磷酯酶Cβ3抗体
合格 Phospho-PLC gamma 1(Ser1248) 磷酸化磷酯酶Cγ1抗体
合格 Phospho-PLC gamma 1 (Tyr783) 磷酸化磷酯酶Cγ1抗体
合格 Phospho-PLK1 (Ser137) 磷酸化丝/苏氨酸蛋白激酶Plk1抗体
合格 Phospho-PSD95 (Tyr236 + Tyr240) 磷酸化突触后密度蛋白95抗体
合格 合格 Phospho-PTEN(Ser380 + Thr382 + Thr383) 磷酸化肿瘤抑制基因PTEN抗体
合格 Phospho-Pin1 (Ser16) 磷酸化肽基脯氨酞顺反异构酶Pinl抗体
合格 Phospho-Progesterone Receptor(Ser190) 磷酸化孕**受体抗体
合格 Phospho-RPS6KA1 (Thr359 + Ser363) 磷酸化丝氨酸/苏氨酸激酶p90RSK蛋白抗体
合格 Phospho-RPS6KA1 (Thr573) 磷酸化丝氨酸/苏氨酸激酶p90RSK蛋白抗体
合格 phospho-c-Raf (Ser289) 磷酸化原癌基因c-Raf抗体
合格 Phospho-RASGRF1 (Ser916) 磷酸化Ras特异性鸟嘌呤核苷酸释放因子1
合格 Phospho-RPS6 (Ser235+Ser236) 磷酸化S6核糖体蛋白抗体
合格 Phospho-MEK4 (Ser257 + Thr261) 磷酸化丝裂原活化蛋白激酶激酶4抗体
合格 合格 Phospho-SGK1 (Ser422) 磷酸化糖皮质**调节激酶1抗体
合格 Phospho-INPPL1(Tyr1135) 磷酸化肌醇聚磷酸盐磷酸酶样蛋白1抗体
合格 phospho-PYK2 (Tyr402) 磷酸化富含脯氨酸的酪氨酸激酶2抗体
合格 phospho-PYK2 (Tyr881) 磷酸化富含脯氨酸的酪氨酸激酶2抗体
合格 合格 Phospho-INPPL1(Ser576) 磷酸化肌醇聚磷酸盐磷酸酶样蛋白1抗体
合格 合格 Phospho-SMC1 (Ser360) 磷酸化染色体结构维持蛋白质１抗体
合格 Phospho-SMC1(Ser957) 磷酸化染色体结构维持蛋白质１抗体
合格 合格 phospho-SHC (Tyr349) 磷酸化SH2结构域转化蛋白1抗体
合格 phospho-SHC (Tyr427) 磷酸化SH2结构域转化蛋白1抗体
合格 Phospho-SirT1 (Ser27) 磷酸化沉默调节蛋白1抗体
合格 合格 Phospho-Smad2(Ser465 + Ser467) 磷酸化细胞信号转导分子SMAD2抗体
合格 Phospho-Smad2(Ser245 + Ser250 + Ser255) 磷酸化细胞信号转导分子SMAD2抗体